In 308 adults with DMARD-naïve rheumatoid arthritis, a tailored treat-to-target strategy (first DMARD by autoantibody status, intensification at 1 month) was not superior to routine care: ts/bDMARD use at 10 months 21% vs 17%; mean DAS similar.
RCTn = 308
Looijen et al. Exploring possibilities towards PeRsonalIsed MEdicine in Rheumatoid Arthritis (PRIMERA): tailored modifications to standard treat-to-target management-a multicentre, randomised, open-label trial